¡@

¤l®cÀVÀù»P¤l®cÀVÀù«e´Áªº¨¾ªv ²Ä¥|³¹¸`

 

¤¤µØ¥Á°ê½Ã¥Í¸p¤l®cÀVÀù¨¾ªv±Ð§÷

ªø©°¬ö©ÀÂå°|´¿§Ó¤¯Âå®v¼¶½Z

 

¤l®cÀV©Ù¤ùµ²ªG³B²z

 

¥¿±`©Ù¤ùªº³B²z¡G

Normal (WITHIN NORMAL LIMIT)

    Normal                                                                                        (Class I)           (1)

    Inflammation or repair                                                               (Class II)          (2)

    Atrophy                                                                                       (Class II)          (3)

 

¡]1¡^          ¤l®cÀV©Ù¤ù¦pªG¬O¥¿±`¡A «h½Ð¤@¦~©w´Á°µ¤@¦¸©Ù¤ùÀˬd¡C

¡]2¡^          ¦pªG¤l®cÀV©Ù¤ù³sÄò¤T¦~¬O¥¿±`¡B ©Î¬O¤C¤Q·³¥H¤W°ü¤k¡B©Î¬O¤l®c¦]¨}©Ê¯e¯f©Î¸~½F¦Ó§¹¥þ¤Á°£ªº°ü¤k¡A «h½Ð¨C¤T¦~©w´Á°µ¤@¦¸©Ù¤ùÀˬd¡C

 

²§±`©Ù¤ùªº³B¸m¡]LGSIL, HGSIL, ASCUS, AGCUS¡^¡G

LGSIL¡]Low Grade Squamous Intraepithelial Lesion¡^¡AHGSIL¡]High Grade Squamous Intraepithelial Lesion¡^¡AASCUS¡]Atypical Squamous Cell of Undetermined Significance¡^¤ÎAGCUS¡]Atypical Glandular Cell of Undetermined Significance¡^

 

n         ©Ù¤ù§PŪµ²ªG¬°·P¬V®É (¥i¦h¿ï)

(1) Candida¡]2¡^Trichomonas¡]3¡^Herpes infection¡]4¡^Human papilloma virus 5¡^chlamydiae¡]6¡^Others

 

¡]1¡^      ¦p©Ù¤ù¬°µoª¢¡B²üº¸»X¯Ê¥F¡BÅðµß·P¬V¡B ³±¹DºwÂηP¬VªÌ¡A «h¦^ªù¶EÀˬdªvÀø (¥H§Ü¥Í¯À¡B ©Î²üº¸»X¡B©ÎÅðµßÃĪ«¡B ³±¹DºwÂÎÃĪ«ªvÀø)¡A µM«á©ó¤T­Ó¤ë«á­«½Æ°µ©Ù¤ù¡C

¡]2¡^      ¦pªG©Ù¤ù¬°ºÃ¤HÃþ¨Å¬ðª¬¯f¬r·P¬V¡A«h½Ð¦^ªù¶E°µ¤HÃþ¨Å¬ðª¬¯f¬r°ò¦]ÀË´ú¤Î³±¹DÃèÀˬd¡C

¡]3¡^      ¦p©Ù¤ù¬°¤ÏÂеoª¢, «h¶·¦Ü°ü²£¬ì¤l®cÀV³±¹DÃè¯S§Oªù¶E¡A ¥Ñ°üÀù±M¬ì¥DªvÂå®v°µ¶i¤@¨B³±¹DÃèÀˬd¤Î¤Á¤ù¡C©Î¬O¥i¥H¨ìªù¶E½Ð°üÀù±M¬ì¥DªvÂå®v°µ¤HÃþ¨Å¬ðª¬¯f¬r°ò¦]ÀË´ú¡A¦p¨S¦³°ª¦MÀI¤HÃþ¨Å¬ðª¬¯f¬r·P¬V¡A «h¥i¥H¦b¤T­Ó¤ë«á­«°µ¤@¦¸©Ù¤ùÀˬd¡A¬Ý¬O§_»Ý¦Aªñ¤@¨B³B¸m¡C¦p¦³°ª¦MÀI¤HÃþ¨Å¬ðª¬¯f¬r·P¬V¡A «h¥²¶·§@³±¹DÃèÀˬd¤Î¤Á¤ù¡C

 

n         ©Ù¤ù§PŪµ²ªG¡]½Ðª½±µ°é¿ï¸¹½X¡A¥u¥i³æ¿ï¡^

Atypical Cells of Undetermined Significance (ASCUS)

Atypical squamous cells                                                  (Class II)          (4)

Atypical glandular cells                                           (Class II)          (5)

Atypical glandular cells                                           (Class II)          (5)

 

¡]1¡^          ½Ð¦Ü°ü²£¬ì¤l®cÀV³±¹DÃè¯S§Oªù¶E¡A ¥Ñ°üÀù±M¬ì¥DªvÂå®v°µ¶i¤@¨B³±¹DÃèÀˬd¤Î¤Á¤ù¡C

¡]2¡^          AGCUS°£¤F³±¹DÃèÀˬd¥~¡A©|»Ý±µ¨ü¤À¬q¦¡¤l®c¤º½¤·k¨í¨ú¼Ë¡]Fractional D¡®C¡^¡C

¡]3¡^          ¤]¥i¥H¨ìªù¶E½Ð°üÀù±M¬ì¥DªvÂå®v°µ¤HÃþ¨Å¬ðª¬¯f¬r°ò¦]ÀË´ú¡A¦p¦³°ª¦MÀI¤HÃþ¨Å¬ðª¬¯f¬r·P¬V¡A «h¥²¶·§@³±¹DÃèÀˬd¤Î¤Á¤ù¡C¦p¨S¦³°ª¦MÀI¤HÃþ¨Å¬ðª¬¯f¬r·P¬V¡A «h¥i¥H¦b¤T­Ó¤ë«á­«°µ¤@¦¸©Ù¤ùÀˬd¡A¬Ý¬O§_»Ý¦Aªñ¤@¨B³B¸m¡C

 

n         ©Ù¤ù§PŪµ²ªG¡]½Ðª½±µ°é¿ï¸¹½X¡A¥u¥i³æ¿ï¡^

Lowgrade Squanous Intraepithelial Lesion (LSIL)

    HPV¡Ðrelated changes                                            (Class II)          (6)

    Mild dysplasia (CIN I)                                             (Class III) (7)

High Grade Squanous Intraepithelial Lesion (HSIL)

   Moderate dysplasia (CIN2)                                       (Class III) (8)

   Severe dysplasia (CIN3)                                            (Class IV)        (9)

   Carcinoma In situ (CIN3)                                         (Class IV)        (10)

Squamous Cell Carcinoma                                           (Class V)         (11)

Adenocarcinorma                                                          (Class V)         (12)

Non Epithelial Neoplasm                                                                   (13)

Others                                                                                                        (14)

 

¡]1¡^          ¤l®cÀV©Ù¤ù¦pªG²§±`ªÌ¡A¥]¬A¡G LSIL, HSIL, ¤Î CANCER¡A «h¶·¦Ü°ü²£¬ì¤l®cÀV³±¹DÃè¯S§Oªù¶E¡A ¥Ñ°ü¤kÀù¯g±M¬ì¥DªvÂå®v°µ¶i¤@¨B³±¹DÃèÀˬd»P¤Á¤ù¡A ¥H¤Î¤HÃþ¨Å¬ðª¬¯f¬r°ò¦]ÀË´ú¡C

¡]2¡^          ¦pºÃ¦³¤l®cÀV¤ºÀV¯fÅÜ¡A «h¶·§@¤l®cÀV¤ºÀV·k¨í¤Á¤ù¡C


³±¹DÃèÀˬd

 

¤l®cÀVÀùªºÀˬd­º¥ý«K¬O­n¾a©w´Áªº¤l®cÀV©Ù¤ùÀˬd¡A¤l®cÀV©Ù¤ùÀˬd¦pªG¦³²§±`¡A«K»Ý­n°µ¶i¤@¨Bªº¤l®cÀV³±¹DÃèÀˬd¡C¬Æ»ò¬O¤l®cÀV³±¹DÃèÀˬd©O¡H³±¹DÃè¬O¥Ñ¼w°êº~³ù¤j¾Ç¤@¦ì°ü²£¬ìÂå®v¥sHinselmann¡A¦b¦è¤¸1925©Ò³]­p¦Ó¶}©l¨Ï¥Î¡A¦Ü¤µ¤w³Q¼Ú¡B¬ü¡B¤éµ¥¥ý¶i°ê®a¼sªx¦b±Ä¥Î¡C¤l®cÀV³±¹DÃè¬O¤@ºØ¥i¥H±N¤l®cÀV©ñ¤j4 ¨ì 30 ­¿ªº¤l®cÀVÀˬd¤ºµøÃè¡C¨ä¹ê¤l®cÀV­Y¥u¾a¦×²´Æ[¹î¦³®É¬O«ÜÃø±N¥¦Àˬd²M·¡ªº¡A¥i¬O¤l®cÀV³±¹DÃè«o¥i¥H±N¤p¤pªº¤l®cÀV©ñ¤j¨ì«D±`²M·¡ªº¦a¨B¡A¤l®cÀV¤W¦pªG¦³¤l®cÀVÀùªº²Ó­M¯fÅÜ¡A©Î¬O¦³§Ö­nÅܦ¨¤l®cÀVÀùªºÀù¯g«e´Á²Ó­M¯fÅÜ¡A³£¥i¥H¦b¤l®cÀV³±¹DÃè¤U¦­´Áµo²{¡C¤l®cÀV©Ù¤ùÀˬd¹ï¤l®cÀVÀù©Î¤l®cÀVÀù«e´Á¯fÅܪº¶EÂ_¨Ã¤£¬O¸U¯àªº¡A¤@¯ë¦Ó¨¥¡A¤l®cÀV©Ù¤ùÀˬd¹ï¤l®cÀVÀù©Î¤l®cÀVÀù«e´Á¯fÅܪº¶EÂ_²v¬ù¥u¦³¦Ê¤À¤§¤C¤Q¥ª¥k¡A¦ý¬O¦pªG¥[¤W¤l®cÀV³±¹DÃèÀˬd¡A¨º»ò¹ï¤l®cÀVÀù©Î¤l®cÀVÀù«e´Á¯fÅܪº¶EÂ_²v«K¥i¥H¹F¨ì¬ù¦³¦Ê¤À¤§¤E¤Q¤­¥ª¥k¡A¦]¦¹¥i¥H´î§C¤l®cÀV©Ù¤ùªº°°³±©Êµo¥Í¡A©Ò¥H¬°¤F´£°ª¤l®cÀVÀùªº¦­´Á¶EÂ_²v¡A¤l®cÀV³±¹DÃèÀˬd«KÅã±o«D±`­«­n¤F¡A¦]¦¹¬O°ü¬ìÂå®v¦bÁ{§É¤W¦­´Á¶EÂ_¤l®cÀVÀù¤£¥i©Î¯Êªººë¾U»ö¾¹¡C§ÚÁ|¤@­Ó¨Ò¤l¡A©Ù¤ùÀˬdµ²ªG¬°ASCUS (Atypical Squamous Cells of Undeterminde singnificance) ¤¤¬ù¥iµo²{20% ¦³¤W¥ÖÅܲ§²Ó­M (Dysplasia , CIN) ¥H¤Wªº¯fÅÜ¡A©ó¨ä¤¤¬ù¦³80% ¬°§C«×ÅÜ©Ê (low grade dysplasia)¡A¬ù¦³20%¬°°ª«×ÅÜ©Ê (high grade dysplasia)¡C³o²{¶H»¡©ú©ó©Ù¤ù¿zÀËÄÝ©óASCUS¤¤¤]¦³¤W¥ÖÅܲ§²Ó­M (CIN) ¤§¦s¦b¡A·í©Ù¤ùÀˬd¬°²§±`®É¡AÀ³¦b³±¹DÃè¾É¤Þ¤U°µ¤Á¤ù¡A¥H¨ú±o§ó¦³¥Nªí©ÊªºÀËÅé¡A ¥HÁקK¤£¥¿½Tªº²Õ´¤Áªk³y¦¨¶EÂ_¤Wªº¿ù»~¡C

 

³±¹DÃè°£¤FÀ°§U°µÀˬd¶EÂ_¥~¡A²{¤µ¤l®cÀV³±¹DÃ誺µo®i¡A¤w¶i¤@¨Bµo®i¨ì¦³¹qµø¼v¹³ªº³±¹DÃè¡A ¦P®É¤]¥i¨Ï¥Î¹qµø¨t²Î´£¨Ñ§ó¦nªºÂå¯f·¾³q¡B ¬Û¤ù¯f¾ú¬ö¿ý¡B»P±Ð¾Ç¤§¥Î¡A ¦]¬°¦³¹qµø¼v¹³¥\¯à¡A©Ò¥H¯f±w¦b±µ¨üÀˬd®É¡A¤]¥i¥H¬Ý¨ì¦Û¤vªº¯e¯f±¡§Î¡A©Ò¥H¯f±w¹ï¦Û¤vªº¯e¯f¡A ·|¦³§ó¥R¥÷ªº¤F¸Ñ¡C¶Ç²Î°ü²£¬ìÀˬd¡A¥D­n¬O¾aÂå®v¹ï¯f±wªº¤º¶E¤Îµø¶E¡AµM«á¥ÑÂå®v±N¯f±¡»¡©úµ¹¯f¤HÅ¥¡A ¦]¬°¯f¤H¬Ý¤£¨ì¦Û¤vªº±w³B¡]¨Ò¦p¡G³±¹D©Î¤l®cÀVµ¥³¡¦ì¡^¡A©Ò¥H¯f±w¹ï¦Û¤v¯e¯fªº¤F¸Ñ¡A ¥²¶·¸g¥ÑÂå®v¹ï±w³Bªº§Î®e±Ô­z¡A¦]¦¹¯f±w¥u¯à¶¡±µÀò±o¹ï¦Û¤v¯e¯fªº²Ê²¤¦L¶H¡A¦ý¬O¹qµø¼v¹³ªº³±¹DÃè³]³Æ¥i¥H§JªA³oºØ¶Ç²Î°ü²£¬ìÀˬdªº¯ÊÂI¡C²{¤µ¦]¹qµø¼v¹³³±¹DÃ誺µo®i¡A¨Ï¯f±w¹ï¦Û¤v¯e¯fªº¤F¸Ñ¡A¥i¥H¸g¥Ñ¹qµø¼v¹³ª½±µÅã¥Ü±w³B¡A¥i¥H©MÂå®v¦P¨BÆ[¹î¡A¦³§U©óÂå®v¹ï¯e¯fªº¸ÑÄÀ¡B´£°ª¯f¤H¹ï¦Û¤v¯e¯fªº±µ¨ü«×¡B¤Î§ïµ½Âå¯fÃö«Y¡A¨Ò¦p¯f¤H¹ï¤l®cÀV¯e¯fªºÄY­«µ{«×¡A»PªvÀø«áªº§ïµ½®ÄªG¡A ¯f±w³£¥i¸g¥Ñ¹qµø¼v¹³±w³BªºÆ[¹î¡A¦Ó¥i¥H±o¨ì¥R¥÷ªº¤F¸Ñ¡A¦Ó¦³§U©óÀˬd»PªvÀø¦¨®Ä¤Î¤é«áªº°lÂÜ¡C¹qµø³±¹DÃè°£¤F¥i¥H¥Î¦bÁ{§ÉÂåÀø¥~¡A ¦]¬°¦³¹qµø¼v¹³¿ý¼v¥\¯à¡A ©Ò¥H¦b±Ð¾Ç¤W¥ç¦³­«­n»ù­È¡C ¦]°ü²£¬ìªù¶E¯f¤HªºÁô¨p»Ý¨D¡A®e©ö³y¦¨±Ð¾Ç¤Wªº§xÂZ»P¤£«K¡A ¦Ó¦¹³]³Æ¥i¥H§JªA°ü²£¬ìÁô±Kªº¯S®í©Ê¡A ¦]¦¹¡A¦¹³]³Æ¤£¶È¥i¥Î¦bÂå°|Á{§É¶EÂ_ªvÀø¡A¨Ã¥i¸g¥Ñ¼v¹³¬ö¿ý©Î¿ý¼v¡A ¦Ó´£¨Ñ¨}¦nªº¾Ç®ÕÁ¿°ó±Ð¾Ç±Ð§÷¡C²{¤µ¼Ú¬ü¤£¶È¤w¼sªx¨Ï¥Î©óprimary care ¡A¦P®É¨Ã¤w¦¨¬°°ü²£¬ìÂå°|ªºµûŲ°ò¥»³]³Æ¤§¤@¡C¦]¦¹±À¼s©Ù¤ù¿zÀË­p¹º¡A±©¦³²Ó­M¾Ç¿zÀË¡B³±¹DÃ褧¤À¯Å¡B©w¦ì¤Á¤ù¡A¥H¤Î¥¿½Tªº²Õ´¾Ç§PŪ©Ò²Õ¦¨ªºª÷¤T¨¤¡A¤l®cÀVÀùªº¨¾ªv­p¹º¤~¯à¸¨¹ê¦Ó¦³®Ä¯q¡C

¤£¹L¦b¼Ú¬w³±¹DÃè¬O°ü¬ìÀˬdªº±`³W¡C¦b­^¬ü¦]ÂåÀø¶O¥Î©ù¶Q¡A³±¹DÃè¥u¥Î¦b¤U¥Í´Þ¹D²Ó­M¾ÇÀˬd¡AÃhºÃ¦³¯fÅܮɡC°ê¤º³±¹DÃ誺¨Ï¥Î¡A°¾ªñ¬ü°êªº¤è¦¡¡C¥H¤U¤¶²Ð¦p¦óµ½¥Î³±¹DÃè¡A¥H´£°ª¹w¨¾¤ÎªvÀø°üÀù¯e¯fªº®ÄªG¡C

 

­þ¨Ç¤H»Ý­n±µ¨ü¤l®cÀV³±¹DÃèÀˬd©O¡H

Á{§É¤W³QÃhºÃ¦³¿©±w¤l®cÀVÀù¡B¤l®cÀVÀù«e´Á¯fÅÜ¡B©Î¬O¦³¤l®cÀV©Ù¤ù¤£¥¿±`ªº¤H¡A´N»Ý­n°µ¶i¤@¨Bªº³±¹DÃèÀˬd¡C

 

³±¹DÃèÀˬd¤è¦¡»P¬yµ{¡G

 

¾÷¾¹¡G¦³¦hºØ³±¹DÃè¾÷¾¹¡A ¥]¬A¡GOlympus¡B Zeiss¡B Leisegang  µ¥¡C

 

Àˬd¤èªk¡G°ü¤k±µ¨ü¤l®cÀV³±¹DÃèÀˬd¬O§¹¥þ¤£·|µhªº¡A¥ç¤£»Ý­n³Â¾K¡AÀˬdªº¤èªk»P§@¤l®cÀV©Ù¤ùÀˬd§¹¥þ¤@¼Ë¡A¥u¬O¦A¥[¤W¨Ï¥Î³±¹DÃè¨ÓÀˬd¤l®cÀV¦Ó¤w¡C

Àˬd«e¡A ¶·¥ý¦bªì¨BÆ[¹î«á¡A ¥H3% ¨ì5% ªº¾L»Ä²Gªg¬V³±¹D¤Î¤l®cÀVªí¥Ö¥HÀ°§U²M°£ÂH²G¤Î¬V¦â¡A³o¼Ë¥i¥H¨Ï±oÀˬdµ²ªG§ó¬°·Ç½T¡A¦Ó¾ã­ÓÀˬd®É¶¡¥u»Ý­n¤T¨ì¤­¤ÀÄÁ´N¥i§¹¦¨¡C¾L»Ä²Gªº®Ä¥Î¥u¯àºû«ù¤@¤ÀÄÁ¥ª¥k¡A©Ò¥H¦p¶WÀˬd¶W¹L¤@¤ÀÄÁ¡A «h¶·¦A¦¸¥H¾L»Ä²Gªg¬V¤l®cÀV¡C

Àˬd«á¡A ¶·±NÆ[¹î©Ò¨£Ã¸¹Ï¬ö¿ý¦b¯f¨Ò¤W¡A ¨Ã±NÃhºÃ¯fÅܳB¼Ð©ú¥X¨Ó¡A ¦p¦³§@¤Á¤ù¡A ¨Ã¶·±N¤Á¤ù³B¬ö¿ý¤U¨Ó¡A ¨Ã±N¯fÅܤj¤p´y¯À¡C¦p¦³¼Æ¦ì¦L¬Û¾÷¡A©Î¬O¹q¸£±m¦âø¹Ï¾÷¡B³s½u¡A«h¥i±N³±¹DÃè©Ò¨£¡A ¥H¬Û¤ù¹Ï§Î¦L¥X¦sÀÉ ¡C

 

³±¹DÃ褧§@¥Î

¦]¬°¦b³±¹DÃè¤U§Ú­Ì¥i¥H±N¤l®cÀVÀù«e´Á¯fÅܩάO¤l®cÀVÀù¬Ýªº«Ü²M·¡¡A©Ò¥H¦b¤l®cÀV³±¹DÃè¤U©Ò°µªº¤l®cÀV¤Á¤ù¡A¥i¥H«Ü·Ç½Tªº¿ï¾Ü¦b¦³¯f¨_ªº¦a¤è°µ¤Á¤ù¡A¤Á¤ùªº²Õ´¦A¸g¥Ñ¯f²z¬ìÂå®v§PŪ¶EÂ_¡A³o¼Ë«K¥i¥H¼W¥[¤l®cÀV¶EÂ_ªº¥¿½T©Ê¡C

 

¤@¡B¤l®cÀVÀù¡G

1.½T©w¯fÅܪº½d³ò¡G«]­­¦b¤l®cÀV©Î¦³©µ¦ù¨ì³±¹D¡A¥i´£¨ÑªvÀø¤è°wªº¿ï¾Ü¡C

2.¿ï¾Ü¾A·íªº¦ì¸m°µ¤Á¤ù¡G§ä¥X³Ì¤£¥¿½T©Î¦³ÃhºÃªº¦ì¸m°µ¤Á¤ù¡AÁקKÀH·N°µ4-6­Ó¤Á¤ù¡A¥B¥i´î¤Ö¤£¥²­nªº¤l®cÀV¶êÀ@¤Á°£¡C

3.»²§UÀù«e´Á¯fÅܪºªvÀø¡G¦b³±¹DÃ誺«ü¤Þ¤U¡A¨Ï¥Î¤M¤ù¡BÂëµ·¹q°é¡]LEEP¡^©Î¤G®ñ¤ÆºÒ¹p®g°µ§½³¡ªvÀø©Î¶êÀ@¤Á¤ù®É¡A³±¹DÃè¥iµo´§Åã·L¤â³Nªº®Ä¥Î¡A¥i¹F¨ì§ó¦nªºªvÀø®ÄªG¡C

4.µû¦ô·s»²§U©Ê¤Æ¾ÇªvÀø®ÄªG¡G¥iÂǥѳ±¹DÃèÀˤñ¸û¤Æ¾ÇªvÀø«e«áªº¸~½FÅé¿n¤j¤pÅܤơAªí­±³W«h©Ê¡B¦åºÞ¯S¼x¡B¶î¬V¾L»Äªº¯S©Ê¨Ó§PÂ_¨ä®ÄªG¡A¥H¨M©w«áÄòªvÀø¤è°w¡C

5.µû¦ô©ñ®g½uªvÀø®ÄªG¡G±µ¨ü©ñ®g½uªvÀø¤j¬ù3000rads®É¡A¤Îµ²§ô«á¥i¤À§O°µ³±¹DÃèÀˬd¨Ó§PÂ_¨ä®ÄªG¡A¥H¨M©w«áÄòªvÀø¤è°w¡C

6.¥ô¦óµ²§ôªvÀø«áªº°lÂÜ¡G¤@¦ý¤S¦³¤£¥¿±`©Ù¤ù¥X²{¡A³±¹DÃèÀˤξA·í¤Á¤ù¬O¨M©w°l¥[ªvÀøªº§Q¾¹¡C

 

¤G¡B³±¹DÀù¤Î¥~³±Àù¡G

1.    ½T©w¯fÅܪº½d³ò¡A°µ¾A·í¦ì¸mªº¤Á¤ù¡C

2.    »²§UÀù«e´Á¯fÅܪºªvÀø¡C

3.    µû¦ô©ñ®g½uªvÀø¡]©Î¦X¨Ö¤Æ¾ÇªvÀø¡^ªº®ÄªG¡C

4.    ªvÀø«á°lÂÜ¡C

 

¤T¡B¤l®c¤º½¤Àù¤Î¤l®c´c©Ê¦×½F¡G

 ¨ó§UŲ§O¶EÂ_¡G·í©Ù¤ù³ø§i¬°¸¢Àù²Ó­M®É¡A¥iÂǥѳ±¹DÃè¤Î¤Á¤ù¨ó§U§PÂ_¬O¤l®cÀV¸¢Àù©Î¤l®c¤º½¤Àù¡]©Î¦³¦X¨Ö¤l®cÀV«I¥Ç¡^¬Æ©ÎÂಾ©ÊÀù¡]¨Ò¡G¥iÂǥѳ±¹DÃè¤Î¤Á¤ù¨ó§U§PÂ_µø¬°¤l®cÀV®§¦×¡B¤l®cÀVÀù¡B¤l®c¦Ù½F®Y¥X©Î¤l®c´c©Ê¦×½F®Y¥X¡^¡C

 

¥|¡Bµ³¤ò½¤Àù¡G

­Y³±¹D¦³¯fÅÜ¡AÀ³°µ³±¹DÃè¥HŲ§O¶EÂ_¬O§_¬°³±¹DÂಾ©Î¨ä¥¦¯e¯f¡A¤£¥i«_µM°µ¤Á¤ù¡A¥H§K¤£¥²­nªº¤j¥X¦å¡C

 

¤­¡BÃh¥¥´Á¶¡¦X¨Ö¤l®cÀV¯fÅÜ¡G

´î¤Ö¤l®cÀV¶êÀ@ª¬¤Á°£¡G­Y¦³¤£¥¿±`©Ù¤ù¡A¸g³±¹DÃèÀˬd¡]¦X¨Ö¤Á¤ù¡^«á¡A§PÂ_¯fÅܤ£·|¶W¹L¤l®cÀV­ì¦ìÀù®É¡A¥i±K¤Á°lÂÜ¡A¨Ãµ¥­Ô¥Í²£«á¤»¶g¦b°µªvÀø¡C

 


³±¹DÃè·s°ê»Ú¤ÀÃþ©M³N»y¸ÑÄÀ (1991¦~)¡G

¡]1¡^        satisfactory

¡]2¡^        unsatisfactory¡C

 

¥¿±`³±¹DÃè©Ò¨£¤À¬°

¡]1¡^          ¶ê¬W¤W¥Ö(Columnar epithelium)¡B

¡]2¡^          Å쪬¤W¥Ö(Squamous epithelium)¡B¤Î

¡]3¡^          ²¾§Î±a(Transformation Zone)¡C

 

²§±`³±¹DÃè©Ò¨£¥i¤À¬°

¡]1¡^          ¾L»Ä¶î«á¥Õ¦â¤W¥Ö(Acetowhite epethelium)¡B

¡]2¡^          ÂIª¬ºc³y¡]Punctation¡^¡B

¡]3¡^          Æ^´Oª¬ºc³y¡]Mosaic¡^¡B

¡]4¡^          ¤£¥¿±`¦åºÞ¡]Atypical vessela¡^¡C

¡]5¡^          ¨¤¤Æ¤W¥Ö¡]Leukoplakia¡^¬°¾L»Ä¶î©Ù«e¤w¦¨¥Õ¦â¡C

¡]6¡^          ¨ÅÀYª¬Àã¬Ð¡]Condyloma accuminata¡^

 

¥t¥~¨ä¥L¦UºØ©Ò¨£¥i¤À¬°³±¹DÃè¤UÃhºÃ¬°«I¼í©ÊÀù¯g¡C

 

¤@¯ë¤l®cÀV¤W¥ÖÅܲ§²Ó­Mªº³±¹DÃè¤Uªí²{¡G

n       CIN I¡G¶î¾L»Ä«á¡A§e²{Á¡ªº¥Õ¦â¤W¥Ö¡A¯fÅܤ§³B¬É¿¤²M·¡¡A©ó¤l®cÀV¤f¥k¤W®B¦³«ÜÁ¡ªºÂIª¬¤ÎÆ^´Oª¬ÅܤơC

n       CIN II¡G¬°¤¤µ¥«×¤§²§§Î¤W¥Ö¡]CIN II,HSIL¡^¡A´Áªí­±§e²{¾L»Ä«á¸û«pªº¥Õ¦âÅܤơA¯fÅܤ§³B¬É½u²M·¡¡A¦³©úÅãÂIª¬¤§Æ^´Oª¬ÅܤơC

n       CIN III¡G©ó¤l®c¥~ÀV¤f¥ª¤U³¡¡A¶î¾L»Ä«á¥X²{«Ü«áªº¥Õ¦â¤W¥Ö¤Î«Ü²M·¡ªºÆ^´Oª¬ÅܤơA¯fÅܤ§³B¬É½u«D±`²M·¡¡A¬°¨å«¬ªºÄY­«²§§Î¤W¥Ö¤Î¹s´ÁÀù¯g¤§¯S®í©Ò¨£¡C

n       ¹s´ÁÀù¯g¡G¨ä¤W¥Ö§e²{¾L»Ä«á¸û«p¥Õ´³¨¤¤ÆÅܤƤÎÂIª¬ºc³y¡A¯fÅܤ§¬É½u²M·¡¡C¡C¬V¦â½è¤À§G§¡¤Ã¡A§e²ÓÁû²Éª¬¡C

n       ¤l®cÀVÀù¡]Cervical squamous carcinoma¡^¡G¤l®cÀVÀùªí­±§e²{¤À§G¤£¥¿±`¥B²Ê¤jªº¦åºÞÅܤơA¨äªí­±¥X²{«p¥B¥W¥Y¤£¥­ªº¥Õ¦â¨¤¤Æ¤W¥Ö¡A¥B¯fÅܤ§¬É½u¤£²M·¡¡C

 

¦¹¥~¤]¦³®Ú¾Ú³±¹DÃè¤U©Ò¨£¡A ¨Óµû¦ô¨äÄY­«µ{«×¡A ¨Ã¥H¤À¼Æ¨Ó¹w¦ô¨äÀù«e´ÁÀù¤Æ¶¥¬q (¨£ªþªí)¡CÁ`¤§¡A ¦pªG³±¹DÃè¤U¦³¥ô¦óÃhºÃªº¯fÅܵo²{¡A ³£¥²¶·°µ³±¹DÃè¤Uªºª½±µ¤Á¤ù¡A µM«á¥Ñ¯f²zÂå®v¦bÅã·LÃè¤U°µ²Ó­M²Õ´§PŪ¡C

³±¹DÃè¤Á¤ùµ²ªGªº³B²z¬yµ{¡G

 

©ó©Ù¤ùÀˬdµ²ªG¶EÂ_¬°ASCUS¥H¤W¤£¥¿±`²Ó­M®É¡A¥i°µªñ¤@¨B²Õ´¤Á¤ùÀˬd¡C

1.  Satisfactory¡G ¦p³±¹DÃèÀˬdÄݺ¡·NªÌ¡]Satisfactory¡^¡A§Y¥i¦b³±¹DÃè¤U¶i¦æ¤Á¤ù¤Î¤l®c¤ºÀV·k¨í¨ú¼Ë¡C

2.  Unsatisfactory¡G ¦p³±¹DÃèÀˬdÄݤ£º¡·NªÌ¡]Unsatisfactory¡^¡A©Î¤l®cÀV¤Á¤ù»P©Ù¤ùµ²ªG¦³©úÅã®t¶ZªÌ¡A»Ý±µ¨ü¤l®cÀVÀ@«¬¤Á¤ù¡GKnife conization,  LEEP (Loop Electrical Excisional Procedure) , Laser conization¤Î¤l®c¤ºÀV·k¨í¨ú¼Ë (endocervical curretage)¡C

3.  AGCUS³±¹DÃèÀˬd¦pÄÝ¥¿±`¡A«h©|»Ý±µ¨ü¤À¬q¦¡¤l®c¤º½¤·k¨í¨ú¼Ë¡]Fractional D¡®C¡^¡C

 

©ó°µ²Õ´¤Á¤ù¤§«e¡A¬°¤F¯à°÷·Ç½T±Ä¨ú¼Ë¥»¡A§Ú­Ì¨Ï¥Î3%¡Ð5% ¾L»Ä¶î©óªí­±¡A¦A¨Ï¥Î³±¹DÃèÆ[¹î¡A ¦]¬°¦³¯fÅܤ§³B·|¥X²{¯S®íÅÜ¤Æ (¦p¤W­±©Ò­z)¡A ©Ò¥H©ó½T©w¦³¤£¥¿±`²Õ´¤§¦a¤è¡A¥i¥H¨Ï¥Î²Õ´¤Á¤ù¾¹±ñ¡A°µ¼Ð¹v¨ú¼Ë¡]Target Biopsy¡^¡C

 


¤l®cÀV¤W¥Ö¤ºÂؽF(©ÎºÙ¤l®cÀVÀù«e´Á - CIN¡^ªº¶EÂ_¡G

 

¤l®cÀV¤W¥Ö¤ºÂؽF (¤l®cÀVÀù«e´Á- CIN¡^ªºªº¶EÂ_¡A ­n¾a¤l®cÀV©Ù¤ùÀˬd¡A ¦p¦³²§±`¡A «h»Ý¶i¤@³¡°µ³±¹DÃèÀˬd»P¤HÃþ¨Å¨rª¬¯f¬rÀËÅç¡A ¦pµo²{¦³¯fÅܦa¤è¡A ´N»Ý°µª½±µ©Êªº¤l®cÀV¤Á¤ù(directed biopsy) »P¤ºÀV±Ä¼Ë (¡Aendocervical sampling or ECC)¡A ·íÃhºÃ¦³¤l®cÀVÅã·LÀù²Ó­M»´¥Ç¥i¯à®É (microinvasive invasion )¡A ´N­n¶i¤@³¡°µ¤l®cÀV¶êÀ@¤Á¤ù¨Ó§PÂ_¤F¡C ¶i¨Ó¤]¦³¼s¬°¤j®a±µ¨üªº see and treat ¤è¦¡¨Ó¦X¨Ö¶EÂ_»PªvÀø¡A ¹ï©ó©Ù¤ù¦³°ÝÃDªº¯f¨Ò¡A ·í±µ¨ü³±¹DÃèÀˬdµo²{¦³¯fÅܪº¦a¤è¡A ´Nª½±µ±Ä¦æ°µLEEP ¤Á¤ù¤è¦¡¨Ó²Î¦X²Ä¤@¦¸¤Á¤ù»P¶êÀ@¤Á¤ù¡A ³oºØ·sªº¤è¦¡¡A«Ü²±¦æ©ó­^°ê¡B ¼ÚÁp¡B»P¿D¬w¡C

 

¤l®cÀV¤W¥Ö¤ºÂؽFªº½T©w¶EÂ_¨Ã¤£®e©ö¡A¦³®É·|µo²{¦³©Ù¤ù»P³±¹DÃè¥H¤Î¯f²z²Õ´¤£¬Û²Å¦Xªº²{¶H (discrepancy) ¡A ¤@¯ë»{¬°¤Á¤ù«áªº²Õ´¾Ç¶EÂ_¬O½T©wªº¶EÂ_¡A ¦ý¦bÁ{§É¹ê°È¤W¡A¤Á¤ù³±¹DÃèÀˤU¤Á¤ù¡A¶êÀ@¦æ¤Á¤ù¤Î¤l®c¤Á°£¼Ð¥»ªº¯f²z¶EÂ_¶¡¡A¨ä¤£¤@­P©Ê¬Û·í°ª¡A©Ò¥H³Ì²×¶EÂ_¤´»Ý¨Ì¾Ú°ü¬ìÂå®vªºÁ{§Éºî¦X§PÂ_¡A ¤×¨ä«Iŧ©ÊÀù¦pªG¨S¦³¶EÂ_¥X¨Ó¦Ó·í°µCIN¨ÓªvÀø¡A «h·|©µ»~¯f±¡¡A §Ú­Ì´¿³ø§i¹L¦³4¨Ò Á{§ÉÂå®vÃhºÃ¦³«IŧÀùªº¥i¯à¡A ¦ý¬O©Ù¤ù¡B¤Á¤ù³ø§i¡A ¶êÀ@¤Á¤ù¯f²z³ø§i¡BECC¡B»P¤l®c¤Á°£¤U¨Óªº³Ì²×²Õ´µ²ªG³£¬O CIN III¡A ¦ý¬O°lÂܤ@¦~«á¦b³±¹Dª¼ºÝ³£µo¥Í¦³«IŧÀù´_µo¡A ­«·s½ÆÀË¥H«eªº¯f²z¤Á¤ù¡A µ²ªG¨ä¤¤¤T¨Ò¦b¶êÀ@¤Á¤ùÀËÅé¼W¥[ªº¤Á¤ùslide¤¤µo²{¦³«Iŧ²Ó­Mªº¦s¦b¡C¡@¤@¯ë¤l®cÀV¶êÀ@¤Á¤ùªºÀËÅé­n¤Á10-100 ¤ùªºslide ²Õ´¬Á¤ù¡A §@¬°¯f²z§PŪ¡A ¦pªG¬YÂå°|ªº¶êÀ@¤Á¤ùÀËÅé¥u¤Á8-10 ¤ùªºslide ²Õ´¬Á¤ù¡A ¨º»ò³oºØ¯f²z§PŪ¶EÂ_¥¢»~ªº¾÷·|¦ÛµM´N¼W¥[«Ü¦h¡A ¦¹¥~¦]¬°¦h¦¸ªº¤l®cÀV¤Á¤ù¤]¥i¯à·|¤zÂZ¹ï©ó¬O§_¦³Åã·L«IŧÀù¯fÅܲ`«×»P¼e«×ªº§PÂ_¡A ©Ò¥H¶EÂ_ CIN »PÅã·L«IŧÀù¯fÅܻݭn®É®ÉÂÔ·V¡C

 

Á`¤§¡A ³Ì­«­nªº¬O CIN ªº¶EÂ_¤d¸U¤£¯à±Ä¦æ¶Ç²Îª¼¥Ø¦¡ªº punch biopsy¡A ©Î¬O Fractional D&C¡F CIN »P»PÅã·L«IŧÀùªº¶EÂ_¤èªk­n²Î¦X©Ù¤ùÀˬd¡B³±¹DÃèÀˬd¡B¤HÃþ¨Å¬ðª¬¯f¬rÀËÅç¡B¥H¤Î²Õ´¤Á¤ùÀˬdµ¥¤èªk¨Óºî¦X§PÂ_¡A¤£¥i°¾¤@¡C

 

ªº°ü²£¬ì±Ð§÷¦³°w¹ïCIN ªº¶EÂ_ªvÀøÀ|¸Õ­n³]©w©T©w¦¡ªº¬yµ{¹Ïªí (schema) ¨Ó¤Þ¾É±Ð¨|Âå®v¨Ó¦p¦ó³B¸m¡A ¦ý²{¤µ¤w¸g¦h±ó¸m¤£±Ä¥Î¡A ¥D­n¬O¦]¬°³o¾ã­Ó¹Lµ{ÅܤƦhºÝ¡A «Ü§xÃø¥H©w«¬¤Æ»¡©ú¡A ¦P®É¦¹Ãþ¬yµ{¹Ï¦h¬y©ó¹L©óÁc²Ó½ÆÂø¡A ¦]¦¹¹ï©ó¤l®cÀVÀù«e´Á - CINªº¶EÂ_»Ý­n»Ý­n¤F¸Ñ¤W­z­Ó¤èªk¨Ã¿Ä·|³e³q¤~¬O®Ú¥»¤§¹D¡C

 

¤l®cÀV¤W¥Ö¤ºÂؽF (CIN) ªºªvÀø±Ô­z©ó«á¡G

 

¤l®cÀV¤W¥Ö¤ºÂؽFªº³B²z¤j­P¥i¤À¬°°£¥h¡]ablation¡^©M¤Á°£¡]excision¡^¨âºØ¤è¦¡¡A«eªÌ¦p§N­áªk¡]cryotherapy¡^¡A¹q¿Nªk¡]electrodiathermy¡^¡A¹p®gªk¡]laser vaporization¡^¡F«áªÌ¦p¹p®gÂà´«°Ï¤Á°£¡]transformation zoneexcisionLEEP/LLETZ¡A¶êÀ@¦æ¤Á°£³N¡]conization¡^¤Î¤l®c¤Á°£¡C

¦pªG¶EÂ_±w¦³¤l®cÀVÀù«e´Á¡A¤@¯ë¦Ó¨¥¡A¥u»Ý­n±N¯f¨_³B§½³¡¤Á°£´N¥i¥H (¶êÀ@¤Á¤ùconization)¡A¤l®cÀVÀù«e´Á¥i¤À¬°»´«×¡B¤¤«×¡B»P­««×µ¥¤T­Ó¶¥¬q¡A­««×¤l®cÀVÀù«e´Á´N¬O«UºÙªº¤l®cÀVÀù¹s´Á¡A¤l®cÀVÀù«e´ÁªºªvÀø»Ý­n¦b¤U°µ¤l®cÀV¶êÀ@ª¬¤Á¤ù¡A§¹¾ã¤Á°£¾ã­Ó¯f¨_¡A³o¼Ë¤£¶È¥i¥H¦A°µ¤@¦¸¥¿½Tªº¶EÂ_¡A¤]¥i¥H¦³ªvÀø®ÄªG¡A·íµM³Ì­«­nªº¬O»Ý­n©MÂå®v±K¤Á°t¦X¡C

 

°£¥hªk¡]ablation¡^ªº¬I¦æ±ø¥ó¬°¡G¡]1¡^¦b©Ù¤ù¡B³±¹DÃè¡B¤Á¤ù¤Î¤l®c¤ºÀV·k¨í¤UµL«Iŧ©ÊÀùªºÃÒ¾Ú¡F¡]2¡^¨Ã¨_¦ì©ó¥~¤l®cÀV¡]ectocervix¡^¡A¥B§¹¥þ¥i¥H¬Ý¨£¡F¡]3¡^¨S¦³¤º¤l®cÀV¡]endocervix¡^ªº«I¥Ç¡CªvÀøªº²`«×¬O¦¨¥\»P§_ªº­«­n¦]¯À¡A¯}Ãa²`«×¹F3mm¥iªv¡95%ªº¯f¤H¡A¦ýÁ{§É¤W¤@¯ë«Øij²`«×¹F5mm¸û¾A·í¡C¤Á°£ªkªº¦n³B¬O¦³ÀËÅé¥i¨Ñ¯f²z¶EÂ_¡A¥Hµû¦ôªvÀøªºÃä½t¡]margin¡^¬O§_°®²b¡]free¡^¡A¤Î±Æ°£«IŧÀùªº¥i¯à¡C ¤@¯ë³N«e©Ù¤ù¡B³±¹DÃè¤Î¤Á¤ùµ²ªG»PÀ@ª¬¤Á°£³Nªº²Å¦X²v¬ù¬°60%¡A¬G¥Ø«e°w¹ï¸ûÄY­«ªº¤W¥Ö¤ºÂؽF¡]CIN II, III¡^¡A¤@¯ë«Øij±Ä¤Á°£ªvÀø¡A¥HÁקKªvÀø¤£¨¬¡]undertreament¡^¡C

 

¦b­««×CINªº³B²z¤W¡A³±¹DÃè¾É¤Þªº¹p®g¤â³N©Î¹q¼ö°é¤Á°£³N¨¬¥H¦³®ÄªvÀø95%¥H¤Wªº¯f®×¡C³±¹DÃè¦P®É¥i¥H¦b¤U¥Í´Þ¹DÀù¯g¹w¨¾¤§¥Á²³±Ð¨|¤Wµo´§¥\¯à¡C§Ú­Ì±N«Øij¦b¥þ°ê±À¼s©Ù¤ù¿zÀË­p¹º¥H¨¾ªv¤l®cÀVÀùªº­p¹º¤¤¡A¥²¶·¦P®É±À¦æ³±¹DÃè¹B¥Î¤§°V½m¡C

 

 

ªvÀø¤èªk¡G ¥]¬A¶êÀ@¤â³N¡B¯}Ãa©Ê¤â³N¡A ¥H¤U¦C¤À§O¤¶²Ð¦UºØªvÀø¤è¦¡¡G

1.          §N­áªk¡]Cryosurgical Freezer¡^¡G§Q¥ÎCO2¡]²GÅéºÒ¡^¶W§C·Å¡A¡]Äá¤ó¹s¤U50¢J¡^¡AÀþ¶¡§N­á¨Ï¯fÅܲÕ´Ãa¦º¡A¹F¨ì³Ì¦³®ÄªvÀø®ÄªG¡A¾A¥Î©óºC©Ê¤l®cÀVª¢¡A¤l®cÀVÁSÄê¡A¤l®cÀV²§§Î¤W¥Ö²Ó­M¯fÅÜ¡]CIN I, LSIL¡^¡A¡¦X®É¶¡¥­§¡¬ù6¡Ð8¶g¤º¡C¬I¦æ§N­áªk»Ý²Å¦X¤U¦C±ø¥ó¡]1¡^CIN, grade1-2¡A¡]2¡^¤p¯f¨_¡A¡]3¡^¶È¦ì¦b¤l®cÀV³B¡A¡]4¡^¤l®c¤ºÀV¨í·k¬°³±©Ê¡A¡]5¡^¤Á¤ùµL¤l®c¤ºÀV¸¢Å骺«I¥Ç¡C ©ó§N­á¤â³NªvÀø¬ù2¡Ð3¤ÀÄÁ«á¡A¨Ï¥¦¸Ñ­á¨ú¤U±´ÀY¡C¤@¯ë±Ä¥Îdouble-freeze¤è¦¡¡A§N­áªº½d³ò»Ý¹F±´ÀY¦yºÝ°¼Ãä5mm¥H¤W¡CªvÀø«á¸û¦h¤l®cÀV¯U¯¶¡]cervix stenosis¡^ªº¨Öµo¯g¡C¦³®É»Ý­n°µ1¡Ð3¦¸¤~¯à§¹¥þªv¡¡C­n¨Ï¥Î§N­á¤â³NªvÀø®É¡A»Ý¿ï¾Ü¤l®cÀV¥~¤f¯f¨_½d³ò¤£¤Ó¤j¡A¥Bªí­±»Ý¥­©Zªº¯f¨Ò¤ñ¸û¦n¡C©óªvÀø«á¡AÅ쪬¬Wª¬¤W¥Ö±µ¦X³¡¡]S.C.J¡^·|©¹¤º²¾¨ì¤ºÀV³¡¡A»Ý­n¯S§Oª`·N¡A¦]S.C.J¬O¤l®cÀVÀù¦nµo³¡¦ì¡A ©Ò¥H©óªv¡«á¨C¦~°µ¤@¦¸©Ù¤ùÀˬd®É¡A»Ýª`·N°µ¤ºÀV³¡¨ú¼Ë¡AÁקK¦³º|ºô¤§³½µo¥Í¡C

2.          ¹q¿Nªk¡GªvÀø²`«×¥i¹F1cm¡A¹ï©óCIN I, II®ÄªG«Ü§¹¥þ¡A¹ï©óCIN III«h¦³13%¥ª¥k¥¢±Ñ²v¡AªvÀø®É¦³®É·|«Üµh¡A¬G»Ý¥þ¨­©Î§½³¡³Â¾K¡AªvÀø«á¸û¦hÅÖºû¤Æ¡]fibrosis¡^ªº±¡§Î¡A¦ý¤@¯ë¤£¼vÅT¨ü¥¥¾÷·|¤ÎÃh¥¥¹Lµ{¡C

3.          ¹p®gªk¡G¤G®ñ¤ÆºÒ¡]CO2¡^¹p®gÀ³¥Î©ó°ü²£¬ì¤W¡A¥D­n¬O§Q¥Î¨ä°ª«×¶°¤¤©Ê¤Îºë½T©Êªº¥ú¤l©Ò­Ñ¦³¯à¶q¤§¯S©Ê¡A¨Ï²Õ´²Ó­M¤¤¤ô¤ÀªmÄ˦ӻ]µo¤Î¦Ü¦º¤`¡A¹F¨ì¤Á³Î·»¤Æ¡B¤p¦åºÞ¾®©T¡B¤î¦å¤§¥\¯à¡A ¦]¦¹¬OªvÀø¤l®cÀVÀùÄY­«²§¦ì¤W¥Ö¤Î­ì¦ìÀù¡]¹s´ÁÀù¡^«Ü¦nªº¤èªk¡C¹p®gªk¥i¤Àvaporization, transformation zone excision¤Îconization¤TºØ¤è¦¡¡C¥¢±Ñ²v¬ù5%¥ª¥k¡A¯}Ãa²`«×¦h¦b5-7mm¤§¶¡¡C¸ò¹q¿Nªk¤@¼Ë¡A¦³glandular involvement¯f¤£·|¼vÅTªvÀø¦¨¥\²v¡C¦¹ªvÀø¦b³±¹D¨ü«I¥Ç¡]vaginal involvement¡^®É¯S§O¦³¥Î³B¡A¦]³±¹D¤W¥ÖµL¸¢Åé¥W³´¡A¯}Ãa²`«×¹F2-3mm§Y¥i¡C¯ÊÂI¬O»ö¾¹©ù¶Q¥B¶·¦³¨¾Å@±¹¬I¡C

4.          °ªÀW²v¹qªi¤â³N¤M¾¹±ñ Loop Electrosurgical Instrument¡]LLETZ/LEEP¡^¡G°ªÀW²v¹qªi¤â³N¤M¡]LEEP¡^§Q¥Î°ª¹qªi¤â³N¤M°µÀôª¬¹q·¥À@ª¬¤Á°£¡A¦w¥þ¥B§Ö¤S¤Ö¶q¥X¦å¡A¤â³N®É¶¡¤j¬ù¥u»Ý­n10¤ÀÄÁ¡A¤â³Nªv¡«á¡A¹ï±wªÌªº¥Í¬¡«~½è¤£¨ü¼vÅT¡A ¦P®É¦]ªvÀø²³æ¡B¦¨¥»§C¡A¦bªù¶E´N¥i°µ¡A¥B¥i´£¨Ñ¯f²z¶EÂ_¡CLEEP¥Ñ¹q·¥¦yºÝµo¥X3.8MHZ¤§°ªÀW²v¹qªi©ó±µÄ²¨­Åé²Õ´«á¡A²£¥Í°ª¼ö¥H¹F¨ì¤Á³Î»P¾®©T¤î¦åªº®ÄªG¡A¹ï¾Fªñ²Õ´¶Ë®`¤p¡C©óÄY­«²§§Î¤W¥Ö¤Î¹s´ÁÀù¯g¡]CIN II¡ÐIII HSIL¡^®É¡A§Ú­Ì¥i¥H¨Ï¥Î°ªÀW²v¹qªiÀôª¬¹q·¥¤â³N¤M°µ¤j«¬½u¤l®cÀVÀ@ª¬¤Á°£¡A´£¨Ñ¶EÂ_¤ÎªvÀø¤§¥Î¡C¦pªG1970¬O§N­áÀøªkªº¦~¥N¡A1980¬O¹p®gÀøªk¡A¨º»ò1990±N¬OLEEPªº¦~¥N¡A¦³¨Ç°ê®a¬Æ¦Ü±Ä¦æ LEEPªº ¡¨see and treat¡¨ ªvÀø¤è¦¡¡A ¥i¥H´î¤Öªù¶E©¹ªðªº§xÂZ¡C

5.          À@ª¬¤Á°£¡G¥]¬Acold knife conization, laser conization¤ÎLEEP conization¤TºØ¡A¦b¸û¤j¯f¨_¡A¤£º¡·Nªº³±¹DÃèÀˬd©Ù¤ù©M³±¹DÃèÀˬdµ²ªG¤£¤@­P¡]¬Û®t2grade¥H¤W¡^¡A¤l®cÀV·k¨í¦³¯fÅÜ©ÎÃhºÃ¦³microinvasin®É¡A»Ý¬I¦æ¶êÀ@§Î¤Á°£¡C¤â³N¥X¦å¯Å³N«á¤l®cÀV¯U¯¶¡A»PÀ@§Î¤Á°£ªºªø«×¦³Ãö¡C¤Á°£ªº°ª«×¤Î«]­­©ó¤l®c¤ºÀVªº¯f¨_¡A¬O³N«á¤l®cÀV¯U¯¶ªº­«­n¦]¯À¡CÃö©ópositive conemargin¡]¯S§O¬Opositive endocervical cone margin¡^ªº³B²z¡A¦Ü¤µ¤´²ö°J¤@¬O¡C positive cone margin·|¼W¥[residual disease ©Îtreatment failure ªº¾÷·|¡A«Øij¶i¤@¨B¤Á°£ªvÀø¡C¬Û¤Ïªº one margin status»Presidual disease ©ÎrecurrenceµLÃö¡C¤£¥¿±`ªº©Ù¤ù°lÂÜ¡A¬O¸û­«­nªº¹w«á¦]¤l¡A¦ÓÀ@ª¬¤Á°£«á¡AÀ³¨Ò¦æ°µ¤l®c¤ºÀV¨í·k³N¡]ECC¡^¡C

6.          ¤l®c¤Á°£¡G¦bcancer phobiaªº¯f¤H¡A¦³¨ä¥L°ü¬ì²z¥Ñ¡]¦p¡G¦Ù½F¡B¤l®c©ì««µ¥¡^¡Apositive cone margin¦Ó¯f¤H¤£·Q¦b¥Í¨|µ¥±¡§Î¤U¡A¥i¬I¦æ¤l®c¤Á°£¡A¦ý»Ý´£¿ô¯f¤H¶}§¹¨ì«á¤´¦³0.3-0.4% invasive cancerªº¾÷·|¡A¤´»Ýªù¶E©w´Á°lÂÜÀˬd¡C

   

¦]±wCINªº±wªÌ¡A±`¬O¦~»´¦³¥Í¨|¯à¤Oªº¤k©Ê¡A¬GªvÀø¹ïfertility¤Îpregnancy outcomeªº¼vÅT­È±oª`·N¡C §N¤MÀ@ª¬¤Á°£·|­°§Cfertility¤Î¼W¥[second trimester abortion, preterm delivery©Mlow-birth-weight infantªº¾÷·|¡C¦Ólaser conization·|¼W¥[low-birth-weight infantªº¾÷·|¡C¦Ü©ólaser vaporization¡BLEEP cryotherapy¡Bdiathermy cautery«hµL¼vÅT¡C

 

CINªºªvÀø¦¨¥\²v¡A¤£½×¬Oablation©Îexcision³£¥i¹F95%¡C¦]¶Ë¤f´_­ì´Áªº¥¿±`µoª¢¤ÏÀ³·|¼vÅT©Ù¤ù§PŪ¡A¬GªvÀø«áªº²Ä¤@¦¸©Ù¤ù°lÂÜ¡AÀ³¦Ü¤Ö¦b¤T­Ó¤ë«á¡A¸g¹L2-3¦¸¥¿±`ªº©Ù¤ùÀˬd¡]¨C¥|¨ì¤»­Ó¤ë°µ¤@¦¸¡^¡A¯f¤H¥i¦^Âk¨C¦~¤@¦¸ªº¨Ò¦æ©Ù¤ùÀˬd¡C°w¹ïCINªº«O¦uªvÀø¡A¦bªvÀø«áªº¤K¦~¤º¥i´î¤Ö«Iŧ©ÊÀùªº¾÷·|¹F95%¡A¦ý§Y¨Ïªø´Á¤p¤ß°lÂÜ¡A³o¨Ç°ü¤k¿©±w«IŧÀùªº¾÷·|¤´¬O¤@¯ë¤Hªº¤­­¿¡A¬G«ØijªvÀø«á¦Ü¤Ö°lÂܤQ¦~¡C

 

 

®Ú¾Ú³±¹DÃè¤Á¤ù¯f²z¤À´Áµ²ªG¡A³B¸m¤è¦¡¤À§O»¡©ú¦p¤U

1.       »´«×¤l®cÀV¤W¥ÖÅܲ§²Ó­M¡B ©ÎºÙ»´«×¤l®cÀV¤W¥Ö¤º¸~½F (CIN I¡B©ÎKoilocytic atypia)

¦p¦³»´«×¤£¥¿±`²Ó­Mªº¥X²{¡A ¦p CIN I¡B©ÎKoilocytic atypia¡A¥i¥H¨Ï¥Î°ªÀW¹q¤M¤Á³Îªk (LEEP) ±N¤l®cÀV°µ³¡¤ÀÀ@ª¬¤Á°£¤Î¤l®c¤ºÀV·k¨í¨ú¼Ë¡A¦¹¤èªk¬J¤è«K¤S¸gÀÙ¡A¥u¦b¤l®cÀV®Ç°µ§½³¡³Â¾K¡A¤â³N®É¶¡¤Sµu¡A¦Ó¥B¤S¥i¥HÀò±o²Õ´ÀËÅé°µ¯f²zÀˬd¡A¦P®É¹F¨ì¶EÂ_»P®Úªv¨âºØ¥Øªº¡C

¥i¬O¦¹Ãþ¯f¨_¤]¦³«ì´_¥¿±`ªº¾÷·|¡A©Ò¥H¥i¥H¤£¶i¤@¨B³B²z¡A¥u­n¨Ï¥Î§Ü¥Í¯ÀªvÀø¨Ó¥h°£µoª¢¦]¯À¥H«á¡A¦Ó¥H©Ù¤ù§@¬°°lÂÜ¡A¨C¤T­Ó¤ë¦Ü¤»­Ó¤ë­«°µ¤@¦¸¤@¦¸©Ù¤ùÀˬd»P³±¹DÃè¡A¬Ý¬O§_»Ý¦Aªñ¤@¨B³B¸m¡C¡C

 

2.       °ª«×¤l®cÀV¤W¥ÖÅܲ§²Ó­M¡B ©ÎºÙ°ª«×¤l®cÀV¤W¥Ö¤º¸~½F( CIN II ¡B CIN III)

©ó²Õ´¤Á¤ùÀˬdµ²ªGµo²{¦³°ª«×Åܲ§²Ó­MÃhºÃ®É¡]CIN II; CIN III, or suspicion of microinvasive cancer¡^«h»Ýªñ¤@¨B°µÀ@Åé²Õ´¤Á¤ùÀˬd¡B ¥H¤Î¤l®cÀV¤ºÀV±Ä¼Ë¤Á¤ù¡C¥Ø«e¥H¨Ï¥Î¤j«¬°ªÀW¹q¤M½u°é±N¤l®cÀV°µÀ@ª¬¤Á°£¸û±`³Q¨Ï¥Î¡A¦]¬°¦P®É¥i¥H¹F¨ì¶EÂ_»PªvÀø¨âºØ¥Øªº¡A·íµM¤]¥i¥H¨Ï¥Î¤M¤ù¤Á°£Àøªk¡B ©Î¹p®g¤Á°£Àøªk¡A ¹ï©ó¦p¦³¸û¤jªº¤l®cÀV¯f§ù¡A«h«Øij¨Ï¥Î¤M¤ù¤Á°£Àøªk©Î¹p®g¤Á°£Àøªk¸û¦n¡A ¨Ï¥Î°ªÀW¹q¤M½u°é®É¡A­n¯S§Oª`·NÁקK°ª¼ö®ÄÀ³¦Ó³y¦¨²Õ´¿NµJ¶i¦Ó¼vÅT¯f²z§PŪ¡C¤l®cÀV¶êÀ@¤Á°£«á¡A «áÄòªº¥þ¤l®c¤Á°£¨Ã¤£¼W¥[¨ä¦s¬¡¾÷²v¡C­YÀ@§Î¤Á¤ùªºÃä½t¤´´Ý¯d¯f¨_¡A¥i¦A¬I¦æ¤l®cÀVÀ@§Î¤Á°£¤â³N©Î°lÂÜ¡B ©Î¬O¤~¬I¦æ¥þ¤l®c¤Á°£¡C

¬I¦æ¥þ¤l®c¤Á°£ªº±ø¥ó¦³:

1.           À@§Î¤Á¤ùªºÃä½t¤´´Ý¯d¯f¨_®É¡A 

2.           ¶EÂ_¤´¦³®t²§ (discrepancy) ¥BÃhºÃ¦³Åã·L«Iŧ¯fÅÜ¥i¯à®É ¡A

3.           ¦³Åã·L«Iŧ¯fÅÜ®É (microinvasive cancer)¡A

4.           ¤£¦b¥Í¨|(Complete family) ¥B¬°¤j©ó50·³ªº¤£©ö°lÂܤ§°ü¤k (poor follow-up)¡C

5.           ©Î¬O¦ñ¦³¨ä¥L¶·¤Á°£¤l®c¤§¸~½F®É¡A ¦p Leiomyoma, adenomyosis, endometrial cancer µ¥¡C 

 

·íµM¹ï©ó CIN II¡A ¤]¥i¥H±Ä¥ÎÅJ®g³¡¥÷®ð¤ÆªvÀø(Laser ablation)¡B§N­áªvÀø (cryotherapy)¡B©Î¬O(electrocauterization)µ¥¡A ¦ý¬O¹ï©ó°ª«×¤l®cÀV¤W¥ÖÅܲ§²Ó­M (CIN III)¡B ¤×¨ä¬O¦pÃhºÃ¦³«Iŧ¯fÅÜ¥i¯à®É (suspicion of microinvasive cancer or invasion)¡A «hºÉ¶q±Ä¥Î¤M¤ùÀ@Åé¤Á°£ªk¡B°ªÀW¹q¤M½u°éÀ@Åé¤Á°£ªk¡B©Î¹p®gÀ@Åé¤Á°£ªk¡A ¦L¬°³o¼Ë¤~¥i¥HÀò±o²Õ´ÀËÅé°µ¶i¤@³¡¯f²zÀˬd¡C

 

3.       Adenocarcinoma in situ of the cervix¡G

¦p¯f¤H¤w°±¸g©Î¤£·Q¦A¥Í¤p«Ä¡AÁöµMÀ@§Î¤Á¤ùªºÃä½t¨S¦³´Ý¯d¯f¨_¡A¤´«Øij°µ¥þ¤l®c¤Á°£¤â³N¡C­YÀ@§Î¤Á¤ùªºÃä½t¤´´Ý¯d¯f¨_ªÌ«h¥²¶·¦A¬I¦æ¤l®cÀVÀ@§Î¤Á°£¤â³N¡C­Y¯f¤H§Æ±æ«O¯d¤l®c¡A«hÀ@ª¬¤Á°£Ãä½t°®²b¡A¥B¤l®c¤ºÀV¨í·k³±©Ê¥i¯à¬°¾A·íªvÀø¡C­Y¯f¤H¤£·Q±µ¨ü¤l®c¤Á°£¡A«hcold knife conization¬O¤ñLLETZ¸û¾A·íªºªvÀø¤è¦¡¡C

 

4.       Stage Ia1

Stage Ia1 ªº¶EÂ_­n¾a¤l®cÀVÀ@§Î¤Á¤ù¦Ó«D§½³¡¤Á¤ù¡]punch biopsy¡^¡CÀ@§Î¤Á¤ù³Ì¦n¨Ï¥Î¼Ð¥»Ãä½t¤£·|¦³¿N¨`²ª¸ñªº¤èªk¡]¦p¥Î¤M¤ù¡^¸û²z·Q¡C¼Ð¥»¥²¶·¦³°µ¨t²ÎªºÀ˵ø¡C­Yµo²{¦³¦­´Á«I¥Çªº¯f¨_¡A¥²¶·­n°µ³sÄò¤Á¤ù¨Ó½T©w³Ì¤j«I¥Ç²`«×¡B¯f¨_ªº¼e«×¡B¥H¤Î¬O§_¦³²O¤Ú¦åºÞ«I¥Ç¡]LVS: lymphatic vascular space invasion¡^¡C¹ï©óStage Ia1 ªº¤l®cÀV¤W¥Ö²Ó­MÀù¡B³æ¯Â¤l®c¤Á°£¡B©Î¬OÀ@§Î¤Á¤ù(Ãä½t¨S¦³¸~½F«I¥Ç) ´N¥i¹F¨ì´X¥G100%ªºªv¡²v¡C¿ï¾Ü­n°µ¤l®c¤Á°£©Î¬O¤l®cÀVÀ@§Î¤Á¤ù¡A«hµø¬O§_­n«O¯d¥Í¨|¯à¤O¦Ó©w¡A­YStage Ia1 ªº¤l®cÀV¤W¥Ö²Ó­MÀùµo²{¦³²O¤Ú¦åºÞ«I¥Ç¡A¥i¬I¦æ®Ú°£©Ê¤l®c¤Á°£¡]Radical Hysterectomy¡^©Î²Ä¤G«¬¤l®c¤Á°£ (Modified Radical Hysterectomy)©Î¥þ¤l®c¤Á°£¡]Total Hysterectomy¡^¦X¨Ö°©¬ÖµÄ²O¤Ú¤Á°£¡C

 

5.       Stage Ia2

Stage Ia2ªº¯f¤H¡A¬I¦æ®Ú°£©Ê¤l®c¤Á°£©Î²Ä¤G«¬¤l®c¤Á°£¤l®c¤Á°£³N (Modified Radical Hysterectomy)¦X¨Ö°©¬ÖµÄ²O¤Ú¤Á°£¡C

 

6.       Stage Ib1 ©ÎIIA

Stage Ib1 ©ÎIIaªº¤l®cÀVÀù¡AÀ³¦æ®Ú°£©Ê¤l®c¤Á°£¦X¨Ö°©¬Ö²O¤Úµ²ºK°£³N¡B©Î¬Oª½±µ±µ¨ü©ñ®gªvÀø¡A¨âªÌÀø®Ä®t¤£¦h¡CStage Ib ©ÎIIaªº©ñ®gªvÀøÀ³¥]¬AÅé¥~·Ó®g¡]Teletherapy¡^©MµÄ¤ºªñ±µ©ñ®gªvÀø¡]Brachytherapy¡^¡C

   

 

7.       Stage Ib2

Stage Ib2¡A¸~½FÅé¿n¬Û·í¤jªº¯f¨Ò¡A³æ¿W¾a©ñ®gªvÀø¡A ¦³®É¹ï¸~½F±±¨î¤£¦n¡A¦]¦¹¥i¥H¥ýµ¹¤©¤Æ¾ÇªvÀø¡A µM«á¥[¤l®c®Ú°£³N¤Î°©¬ÖµÄ²O¤Úµ²¤Á°£¡A ©Î¬O¦b©ñ®gªvÀø®É¨Ö¦Pµ¹¤©¤Æ¾ÇªvÀø¡C

¦³¤@¨Ç¦]¤l¦p²O¤Úµ²Âಾ¡B¸û¤jªº¯f¨_¡]¡Ö4¢Q¡^¡B¯f¨_«I¥Ç²`«×¸û²`¡B¸û®tªº¯f²z²Õ´«¬ºA¡B¥H¤Î²O¤Ú¦åºÞ«I¥Ç¡]LVSI¡^µ¥¡A§¡³Q»{¬°¬OÄÝ©ó¹w«á±Ð®tªº¦MÀI¦]¤l¡C

 

¹ï©ó®Ú°£©Ê¤l®c¤Á°£¤â³N¡A ¦p¤â³N«á¼Ð¥»Ãä½t¦w¥þ¶ZÂ÷¤£¨¬©Î¯f¨_¥¼¤Á°£°®²bªº¯f¨Ò¡A³N«á¥i¥H¸É¦æ©ñ®gªvÀø¡A¥i´î¤Ö°©¬ÖµÄ¤º´_µo¡C ®Ú°£©Ê¤l®c¤Á°£«á­Y¯f²z¤Á¤ùµo²{¦³²O¤Úµ²Âಾ¡A³N­Ô«hÀ³¸É°l¥[©ñ®gªvÀø¥i´î¤Ö°©¬ÖµÄ¤º´_µo¡A¦p¶È¦³¤@Áû²O¤Úµ²Âಾ¡A«h¥i¥H¦A¤â³N«á°l¥[¤Æ¾ÇªvÀø¥H´î¤Ö´_µo¡C¦p³N«áµo²{¦³¤l®c®Ç²Õ´Âಾ¡A«hÀ³¸É°l¥[©ñ®gªvÀø»P¤Æ¾ÇªvÀø¡A¹ï©ó¨º¨Ç¦]³N«e¥¼³Q¶EÂ_¥X¨Ó¡B¦Ó·í§@¨}©Ê¯e¯f¦Ó¬I¦æ³æ¯Â¤l®c¤Á°£ªº¤l®cÀVÀù¯f¨Ò¡A¤]À³°l¥[©ñ®gªvÀø¡B©Î¬I¦æ¤l®c®Ç²Õ´¤Á°£¡]parametrectomay¡^©M°©¬Ö²O¤Ú¤Á°£¡C

Ãh¥¥¦X¨Ö¤l®cÀVÀù°ü¤kªº¹w«á¸û«DÃh¥¥°ü¤kªº¬°®t¡C¦ýStage Ia»PIb1ªº¯f¤H¥i¥H©µ«á 2-4 ¶g®É¶¡ªvÀø¡A«Ý­L¨à¦³¨¬°÷¦s¬¡¯à¤O¦A¬I¦æªvÀø¡C

¤l®cÀVÀùªvÀø«á¡A¤£½×­ì¨Ó¬O¦óºØ²Ó­M«¬ºA©Î¤À´Á¡Aµ¹¤©¤k©Ê²üº¸»X¸É¥R¥¿±`©Ê¥Í¬¡¨ÃµL¯S®í¸T§Ò¡C

 

 


1994¦~FIGO´£¥X·sªº¤l®cÀVÀù¤À´Á¤èªk¡]International Federation of Gynecologists and Obstetricians¡^¡C

 

Stage Ia1¤l®cÀVÀù

¤l®cÀVÀù²§±`²Ó­M¦b¤l®cÀV¤W¥Ö¦³°ò©³¼h¯}·l«I¥Ç¡A ¦ý¬O»´¥Ç°ò©³¼h¤U¤§stroma ²`«×¤£¶W¹L 3 mm¡A ¥B¼e«×¤£¶W¹L 7 mm¡C

 

Stage Ia2¤l®cÀVÀù

¤l®cÀVÀù²§±`²Ó­M¦b¤l®cÀV¤W¥Ö¦³°ò©³¼h¯}·l«I¥Ç¡A ¦ý¬O»´¥Ç°ò©³¼h¤U¤§stroma ²`«×¤¶©ó 3-5 mm¡A ¥B¼e«×¤£¶W¹L 7 mm¡C

 

Stage Ib1¤l®cÀVÀù

¤l®cÀVÀù²§±`²Ó­M¦b¤l®cÀV¤W¥Ö¦³°ò©³¼h¯}·l«I¥Ç¡A ¦ý¬O»´¥Ç°ò©³¼h¤U¤§stroma ²`«×¶W¹L 3 mm¡A ©Î¼e«×¶W¹L 7 mm¡C ¦ý¬O¤l®cÀVÀù¸~½F¶È­­©ó¤l®cÀV¡B ¦P®ÉÅé¿n¤p©ó 4 ¤½¤À¡C

 

Stage Ib2¤l®cÀVÀù

¤l®cÀVÀù¸~½FÁö¶È­­©ó¤l®cÀV¡B ¦ý¬OÅé¿n¤j©ó 4 ¤½¤À¡C

 

Stage IIa¤l®cÀVÀù

¤l®cÀVÀù¸~½F°£¤F¦b¤l®cÀV¥~¡B ¦P®É«I¥Ç³±¹D¤W¤T¤À¤§¤G¡C

 

Stage IIb¤l®cÀVÀù

¤l®cÀVÀù¸~½F°£¤F¦b¤l®cÀV¥~¡B ¦P®É«I¥Ç¤l®cÀV®Ç²Õ´¤º°¼¡C

 

Stage IIIa¤l®cÀVÀù

¤l®cÀVÀù¸~½F°£¤F¦b¤l®cÀV¥~¡B ¦P®É«I¥Ç³±¹D¤U¤T¤À¤§¤G¡C

 

Stage IIIb¤l®cÀVÀù

¤l®cÀVÀù¸~½F°£¤F¦b¤l®cÀV¥~¡B ¦P®É«I¥Ç¤l®cÀV®Ç²Õ´¥~°¼¨Ã«I¥Ç¨ì°©¬Ö¾À¡C

 

Stage IVa¤l®cÀVÀù

¤l®cÀVÀù¸~½F°£¤F¦b¤l®cÀV¥~¡B ¦P®É«I¥Ç»H¯Ö©Îª½¸z¡C

 

Stage IVb¤l®cÀVÀù

¤l®cÀVÀù¸~½F°£¤F¦b¤l®cÀV¥~¡B ¦P®É¦³»·³BÂಾ¡C


½Ã±Ð»¡©ú

 

¦p¦ó¹w¨¾¤l®cÀVÀù¡H

´¿¦³¹L©Ê¸gÅ窺°ü¤k¡A¤@¥Í³£¦³¿©±w¤l®cÀVÀùªº¥i¯à¡F¦]¦¹¡A¥u­n¬O¦³¹L©Ê¸gÅ窺°ü¤k¡A¤£½×¦~ÄÖ¤j¤p¡A¨C¦~³£À³©w´Á±µ¨ü¤@¦¸¤l®cÀV©Ù¤ùÀˬd¡A

ªá¤»¤ÀÄÁ®É¶¡°µ¤l®cÀV©Ù¤ùÀˬd¡A´N¥i¥H¤Î¦­µo²{¤l®cÀVÀù«e´Á¯fÅÜ¡A¤Î®ÉªvÀø¡C¤èªk¬O¥H¤p¤ì´Î©Î¤p¨ê¤l¦b¤l®cÀV¤W¡A»´»´¨í¨ú¤Ö¶q²Ó­M¡A¨ÓÀË´ú¤l®cÀV²Ó­M¬O§_¥¿±`¡C¾ã­Ó±Ä¼Ë¹Lµ{³q±`¤£¶W¹L¥b¤ÀÄÁ¡A¦P®É¯f¤H§¡¤£·|·P¨ì¯kµh©Î¤£¾A¡A¬O«D±`²³æ»´ÃPªº¿zÀˤâÄò¡C¤l®cÀV©Ù¤ù¥i¥H¦b¦U¦a½Ã¥Í©Ò©Î°ü²£¬ìÂå°|Àˬd¡A°µ©Ù¤ùÀˬd¤§«e¡A½ÐÁקK¡G¬Ö¯D¡B²M¬~³±¹D¡B¶ëÃÄ¡B©Ð¨Æ¡A¥H§K¼vÅT¶EÂ_¡C

 

¤l®cÀVÀùªº¯gª¬¡G

¤l®cÀVÀù¤À¬°¹s´Á¡B¤@´Á¡B¤G´Á¡B¤T´Á©M¥|´Á¡C¦­´Áªº¤l®cÀVÀù³£¬O¨S¦³¯gª¬ªº¡A ¦p¦³¯gª¬³£¥X²{²Ä¤@´Á¥H¤W¡C±ß´Áªº¤l®cÀVÀù¯gª¬¥]¬A¤£¥¿±`ªº³±¹D¥X¦å¤Î±a¦å¤Àªcª«¡A³o¨Ç¤£¥¿±`ªº¥X¦å¥]¬A¦æ©Ð«á¥X¦å¤Î°±¸g«áªº¥X¦å¡C³q±`¡A°ü¤k¥u­n¨£¨ì²§±`¥X¦å¡A¦h·|¦Û¦æ´NÂå¡C¦ýªv¡²v³Ì°ªªº­ì¦ìÀù¬Æ¦Ü­ì¦ìÀù¤§«eªº¤W¥Ö¤º¯fÅÜ¡B¥H¤Î¦­´Áªº¤l®cÀVÀù¡A«o²@µL¯gª¬¡A°ß¦³¨Ì¾a¤l®cÀV©Ù¤ùÀˬd¤è¯à´ú¤§¡C©Ò¥H°ü¤kªB¤Í­Ì¤@©w­n©w´Á°µ¤l®cÀV©Ù¤ù¡C¹s´Á¤l®cÀVÀùªºªv¡²v´X¥G¥i¥H¹F¨ì100%ªº¡C

 

¤°»ò¤H¸û®e©ö¿©±w¤l®cÀVÀù¡H

¥u­n¦³©Ê¸gÅ窺°ü¤k¡A§Y¦³¿©±w¤l®cÀVÀùªº¥i¯à©Ê¡C¨ä¤¤©Ê¸gÅç¸û¦­¶}©l¡]¦p¤Q¤C·³¥H«e¡^¡A©Ê¦ñ«Q¸û¦h©Î´¿¿©±w©Ê¯fªº°ü¤k¡B ¥H¤Î¿©±w·P¬V¤HÃþ¨Å¨rª¬¯f¬rªº°ü¤k¡A³£¬OÄÝ©ó¤l®cÀVÀùªº°ª¦MÀI¸s¡A¦Ó§l·Ï¤k©Ê±w¯fªº¾÷²v¤]°ª©ó4¥¼§l·ÏªÌ¡C¨ä¦¸¡A¦pªG¤@¦ì°ü¤kªº¨k©Ê©Ê¦ñ«Q´¿·P¬V©Ê¯f©Î©Ê¦ñ«Q²³¦h¡A¬Æ¦Ü´¿¦³¹L¿©±w¤l®cÀVÀù©Î­ì¦ìÀùªº©Ê¦ñ«Q¡A¨º»ò±aµ¹³o¦ì°ü¤k¿©±w¤l®cÀVÀùªº¾÷²v¤]±N¼W°ª¡C

 

¦p¦ó­±¹ïPap smear °²³±©Ê©Ò­l¥Íªº°ÝÃD¡G

³y¦¨¤l®cÀV©Ù¤ùªº°²³±©Ê¡]false¡ÐNegative¡^¤ñ¨Ò¬ù¦³30¡Ð40%¡C1994¦~ACOG§ó«ü¥X³y¦¨¿zÀˤ£¥¿½Tªº¥D­n­ì¦]¦³¤T­Ó¡G

¡]¤@¡^±Ä¼Ë¥¢»~¡]Sampling Errors¡^¡F

¡]¤G¡^§PŪ¥¢»~¡]Evaluation Errors¡^¡F

¡]¤T¡^¬Y¨Ç¤l®cÀVÀù¬Û·íÃø¥H¥Î¤l®cÀV©Ù¤ù°»´ú¥X¡B©Î¦]µo¯f¨³³t¦ÓµLªk¤Î®É¿zÀË¡A ³o¬OµLªkÁקKªº¡C

 

¦]¦¹¡A¦b°µ©Ù¤ù®É¡A©yª`·N¡G

¡]¤@¡^¯f¤H¦b¤ë¸g´Á¶¡¡A¦³³±¹Dª¢¡A¥Õ±a¦h©Î©Ê¥Í¬¡24¤p®É¥H¤º³£À³ÁקK°µ¿zÀË¡C

¡]¤G¡^¨ú¼Ë®É­n¦ì¸m¡]Transformation Zone¡^»P¶î¤ù³£¥¿½T¡A©T©w½T¹ê¡C

¡]¤T¡^­n§iª¾°²³±©Êªº¥i¯à©Ê¡A¨Ã½Ð¯f¤H«ö®É°lÂÜ¡A¥H´Á¡u¦­´Á¶EÂ_¡B¦­´ÁªvÀø¡v¡C